Your Messages Inbox
Your Article Summary
See Latest ArticlesSynthon announces European approvals for generic Rivastigmine
Synthon, 09/10/09
Rivastigmine tartrate is the active ingredient of Novartis' branded product Exelon, which is one of the leading drugs for Alzheimer disease. Exelon is indicated for symptomatic treatment of mild to moderately severe Alzheimer's dementia and for the symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09
Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09
Article Search
Sponsor